Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram

Massachusetts General Hospital60 enrolled

Overview

Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using 18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET).

Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using 18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET). The following hypothesis will be tested: Antidepressant response or remission in depressed BPD patients will be associated with changes in cortical (prefrontal, parietal, premotor) and paralimbic (hippocampus, anterior cingulate, subgenual cingulate, posterior cingulate, and anterior insula) regions, consistent with SRI antidepressant response in unipolar depressed patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Bipolar Depression

Eligibility

Sex: ALLMin age: 18 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Current age 18-64 years; DSM-IV diagnosis of BPD, type-I, or type-II; Enrolled in the Citalopram Study at Tufts Medical Center Exclusion Criteria: * Current pregnancy, or inability to utilize contraception, The presence of any metallic implants, History of claustrophobia

Locations (1)

Massachusetts General Hospital - East

Charlestown, Massachusetts, United States

Outcomes

Primary Outcomes

rCMRglu

regional glucose metabolism

Time frame: pre and post-treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.